ATE273990T1 - Adenosin a1-rezeptor agonisten - Google Patents

Adenosin a1-rezeptor agonisten

Info

Publication number
ATE273990T1
ATE273990T1 AT98965151T AT98965151T ATE273990T1 AT E273990 T1 ATE273990 T1 AT E273990T1 AT 98965151 T AT98965151 T AT 98965151T AT 98965151 T AT98965151 T AT 98965151T AT E273990 T1 ATE273990 T1 AT E273990T1
Authority
AT
Austria
Prior art keywords
adenosine
receptor agonists
agonists
receptor
Prior art date
Application number
AT98965151T
Other languages
German (de)
English (en)
Inventor
Richard Peter Charles Cousins
Brian Cox
Colin David Eldred
Andrew Michael Kenneth Pennell
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE273990T1 publication Critical patent/ATE273990T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT98965151T 1997-11-08 1998-11-06 Adenosin a1-rezeptor agonisten ATE273990T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9723589.9A GB9723589D0 (en) 1997-11-08 1997-11-08 Chemical compounds
PCT/EP1998/007021 WO1999024449A2 (en) 1997-11-08 1998-11-06 Adenosine a1 receptor agonists

Publications (1)

Publication Number Publication Date
ATE273990T1 true ATE273990T1 (de) 2004-09-15

Family

ID=10821760

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98965151T ATE273990T1 (de) 1997-11-08 1998-11-06 Adenosin a1-rezeptor agonisten

Country Status (29)

Country Link
US (1) US6455510B1 (https=)
EP (2) EP1030857B1 (https=)
JP (1) JP2001522857A (https=)
KR (1) KR20010031875A (https=)
CN (1) CN1285843A (https=)
AP (1) AP2000001801A0 (https=)
AR (1) AR011229A1 (https=)
AT (1) ATE273990T1 (https=)
AU (1) AU2048399A (https=)
BR (1) BR9813976A (https=)
CA (1) CA2309200A1 (https=)
CO (1) CO5021135A1 (https=)
DE (1) DE69825780T2 (https=)
EA (1) EA200000392A1 (https=)
EE (1) EE200000285A (https=)
ES (1) ES2222621T3 (https=)
GB (1) GB9723589D0 (https=)
HR (1) HRP20000275A2 (https=)
HU (1) HUP0004082A2 (https=)
IL (1) IL135964A0 (https=)
IS (1) IS5477A (https=)
MA (1) MA26565A1 (https=)
NO (1) NO20002361L (https=)
PE (1) PE20000013A1 (https=)
PL (1) PL340921A1 (https=)
SK (1) SK6722000A3 (https=)
TR (1) TR200002131T2 (https=)
WO (1) WO1999024449A2 (https=)
ZA (1) ZA9810125B (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9723589D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
US20040162422A1 (en) * 2001-03-20 2004-08-19 Adrian Hall Chemical compounds
GB0106867D0 (en) 2001-03-20 2001-05-09 Glaxo Group Ltd Process
US7157440B2 (en) 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7713946B2 (en) 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
EP1434782A2 (en) 2001-10-01 2004-07-07 University of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
US7265111B2 (en) 2002-06-27 2007-09-04 Sanofi-Aventis Deutschland Gmbh Adenosine analogues and their use as pharmaceutical agents
EP1375508A1 (en) * 2002-06-27 2004-01-02 Aventis Pharma Deutschland GmbH N6-substituted adenosine analogues and their use as pharmaceutical agents
FR2842810B1 (fr) * 2002-07-25 2006-01-27 Inst Nat Sciences Appliq Nouveaux composes gem difluores, leur procedes de preparation et leurs applications.
JP4596913B2 (ja) * 2002-08-15 2010-12-15 ギリアード・パロ・アルト・インコーポレイテッド A1アデノシン受容体の部分および完全アゴニスト
KR20050097971A (ko) 2003-02-03 2005-10-10 씨브이 쎄러퓨틱스, 인코포레이티드 A₁아데노신 수용체의 부분 및 전 작용제
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
JP2008512457A (ja) * 2004-09-09 2008-04-24 アメリカ合衆国 A3及びa1アデノシン受容体作用薬としてのプリン誘導体
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
RU2421464C2 (ru) 2005-10-21 2011-06-20 Новартис Аг Человеческие антитела к il-13 и их терапевтическое применение
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
WO2007120972A2 (en) * 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
WO2008037477A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as p13k lipid kinase inhibitors
CN101522682A (zh) 2006-10-30 2009-09-02 诺瓦提斯公司 作为抗炎剂的杂环化合物
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
JP2011509305A (ja) * 2008-01-09 2011-03-24 ピージーエックスヘルス、リミテッド、ライアビリティー、カンパニー A2arアゴニストによる神経障害性疼痛の髄腔内治療
MX2010007604A (es) 2008-01-11 2010-08-02 Novartis Ag Pirimidinas como inhibidores de cinasa.
PT2391366E (pt) 2009-01-29 2013-02-05 Novartis Ag Benzimidazoles substituídos para o tratamento de astrocitomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
JP5781510B2 (ja) 2009-08-12 2015-09-24 ノバルティス アーゲー ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
PE20121148A1 (es) 2009-08-17 2012-09-07 Intellikine Llc Compuestos heterociclicos y usos de los mismos
JP5775871B2 (ja) 2009-08-20 2015-09-09 ノバルティス アーゲー ヘテロ環式オキシム化合物
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
WO2012116217A1 (en) 2011-02-25 2012-08-30 Irm Llc Compounds and compositions as trk inhibitors
DE102011005232A1 (de) 2011-03-08 2012-09-13 AristoCon GmbH & Co. KG Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
EA026655B1 (ru) 2011-09-15 2017-05-31 Новартис Аг 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
CA2856803A1 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
JP2015512425A (ja) 2012-04-03 2015-04-27 ノバルティス アーゲー チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
ES2831416T3 (es) 2014-07-31 2021-06-08 Novartis Ag Terapia de combinación de un inhibidor de MET y un inhibidor de EGFR
CN113194752A (zh) 2018-06-01 2021-07-30 康奈尔大学 Pi3k相关疾病或病症的组合疗法
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法
JP2026500305A (ja) 2022-12-16 2026-01-06 アストラゼネカ・アクチエボラーグ 2,6,9三置換プリン

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3575959A (en) * 1969-05-13 1971-04-20 Merck & Co Inc 5'-substituted ribofuranosyl nucleosides
US5589467A (en) * 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
WO1997033591A1 (en) * 1996-03-13 1997-09-18 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
GB9610031D0 (en) 1996-05-14 1996-07-17 Glaxo Group Ltd Chemical compounds
GB9723589D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
TR200002131T2 (tr) 2001-01-22
HRP20000275A2 (en) 2000-12-31
EP1030857A2 (en) 2000-08-30
NO20002361D0 (no) 2000-05-05
SK6722000A3 (en) 2001-01-18
ES2222621T3 (es) 2005-02-01
HUP0004082A2 (hu) 2001-04-28
DE69825780T2 (de) 2005-01-13
IS5477A (is) 2000-05-03
EE200000285A (et) 2001-08-15
US6455510B1 (en) 2002-09-24
AP2000001801A0 (en) 2000-06-30
PE20000013A1 (es) 2000-01-21
ZA9810125B (en) 2000-05-05
CO5021135A1 (es) 2001-03-27
EP1457495A1 (en) 2004-09-15
NO20002361L (no) 2000-07-05
WO1999024449A3 (en) 1999-08-19
IL135964A0 (en) 2001-05-20
CN1285843A (zh) 2001-02-28
AU2048399A (en) 1999-05-31
EP1030857B1 (en) 2004-08-18
PL340921A1 (en) 2001-03-12
BR9813976A (pt) 2000-09-26
AR011229A1 (es) 2000-08-02
DE69825780D1 (de) 2004-09-23
WO1999024449A2 (en) 1999-05-20
CA2309200A1 (en) 1999-05-20
JP2001522857A (ja) 2001-11-20
KR20010031875A (ko) 2001-04-16
GB9723589D0 (en) 1998-01-07
MA26565A1 (fr) 2004-12-20
EA200000392A1 (ru) 2000-12-25

Similar Documents

Publication Publication Date Title
ATE273989T1 (de) Adenosin a1-rezeptor agonisten
ATE242259T1 (de) Adenosin a1-rezeptor agonisten
DE69825780D1 (de) Adenosin a1-rezeptor agonisten
ATA904399A (de) Adenosin a3-rezeptor-modulatoren
EP0984779A4 (en) SOMATOSTATIN AGONISTS
DE60007127D1 (de) N-pyrazol a2a rezeptor agonisten
DK1192169T3 (da) C-pyrazol A2A receptor-agonister
ATE293627T1 (de) Adenosin a2a rezeptor antagonisten
PT1090019E (pt) Derivados de adenosina
EP0977751A4 (en) SOMATOSTATIN AGONISTS
EP1023061A4 (en) SOMATOSTATINAGONISTE
DK1019075T3 (da) Beta2-Adrenerge receptoragonister
DE60234951D1 (de) Adenosin a2a rezeptor antagonisten
PT1192170E (pt) Agonistas de receptor a2a de propargilfenileter
NO961887L (no) -adrenergiske agonister
DE69835024D1 (de) Allosterische adenosin-rezeptor-modulatore
ID24726A (id) Antagonis-antagonis reseptor trombin
DE69506826D1 (de) 5-HT4 Rezeptoragonisten
ATE231508T1 (de) Azyklische nukleosidderivate
ID24162A (id) Antagonis-antagonis reseptor vitronektin
ATE250621T1 (de) Oral aktive a1 adenosin rezeptor agonisten
DE69012388D1 (de) Selektive Adenosinrezeptor-Verbindungen.
FI955257A7 (fi) 8-substituoidut-ksantiinit valikoivina adenosiinireseptoriaineina
HK1028407A (en) Adenosine a1 receptor agonists
HK1028408A (en) Adenosine a1 receptor agonists

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties